Catalent (CTLT)
(Delayed Data from NYSE)
$59.86 USD
-0.28 (-0.47%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $59.87 +0.01 (0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth D Momentum B VGM
Brokerage Reports
0 items in cart
Catalent, Inc. [CTLT]
Reports for Purchase
Showing records 41 - 60 ( 220 total )
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
GLP-1 Market Opportunity Update, 2028 Consensus Estimates +11% vs. April Report
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
3Q23 - Guidance Granularity, FY24 Needs Sarepta Tailwind
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Poor Execution Behind Preannouncement & CFO Departure
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Obesity/Diabetes Therapeutics, Far Surpassing Estimates
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Model Update with Better Clarity Around Sarepta and COVID
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
2Q23 - Improved Results and Upbeat Cell & Gene Therapy Outlook
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department